Several novel biomarkers, including fibroblast growth factor-23 (FGF-23) and kidney injury molecule-1 (KIM-1), have shown promise in predicting early AKI before a significant rise in Scr. This evidence concerns the gene HAVCR1 and acute kidney injury.